Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic

Схожие документы

• COVID‐19 and immunosuppressive therapy in dermatology
  по: Schwartz, Robert A., et al.
  Опубликовано: (2020)
• The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology
  по: Reinholz, Markus, et al.
  Опубликовано: (2021)
• Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina()
  по: Zimman, S., et al.
  Опубликовано: (2020)
• Considerations for dermatology residency applicants underrepresented in medicine amid the COVID-19 pandemic
  по: Jones, Virginia A., et al.
  Опубликовано: (2020)
• COVID-19 and immunomodulator/immunosuppressant use in dermatology
  по: Price, Kyla N., et al.
  Опубликовано: (2020)